- Conditions
- Obesity
- Interventions
- Oseltamivir
- Drug
- Lead sponsor
- Manjunath Prakash Pai
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Paramaus, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 52
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza A, Influenza B
- Interventions
- Anti-Influenza Immune Plasma, Standard Care
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 35
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California + 22 more
- Conditions
- Pregnancy, Influenza
- Interventions
- Oseltamivir (Tamiflu), Blood Draws
- Drug · Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Influenza
- Interventions
- Oseltamivir IV, Oseltamivir Oral
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more
- Conditions
- Influenza
- Interventions
- Amantadine, Ribavirin, Oseltamivir, Oseltamivir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
- Conditions
- Influenza
- Interventions
- Oseltamivir, Probenecid
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Influenza A
- Interventions
- VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 129
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
- Conditions
- Influenza, Human
- Interventions
- oseltamivir, placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
- Conditions
- Influenza
- Interventions
- Influenza Virus influenza A H3N2 strain
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Prematurity of Fetus
- Interventions
- Oseltamivir
- Drug
- Lead sponsor
- St. Louis Children's Hospital
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Influenza
- Interventions
- oseltamivir [Tamiflu]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Oakland, California • Aurora, Colorado + 30 more
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Influenza, Pneumonia
- Interventions
- oseltamivir
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky
- Conditions
- Bioequivalence
- Interventions
- Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
- Drug
- Lead sponsor
- Austarpharma, LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Edison, New Jersey
- Conditions
- Influenza
- Interventions
- Oseltamivir, Placebo
- Drug
- Lead sponsor
- Marshfield Clinic Research Foundation
- Other
- Eligibility
- 1 Year to 79 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Marshfield, Wisconsin
- Conditions
- Healthy Volunteer
- Interventions
- Oseltamivir, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Austin, Texas
- Conditions
- Influenza
- Interventions
- TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- H1N1 Influenza Treatment During Pregnancy
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil, Placebo, Oseltamivir
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
- Interventions
- pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Influenza A Virus
- Interventions
- JNJ-63623872, Placebo, Oseltamivir
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Fresno, California • Long Beach, California • Stanford, California + 11 more
- Conditions
- Influenza
- Interventions
- Baloxavir, Placebos
- Drug
- Lead sponsor
- Bassett Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Springfield, Massachusetts • Cooperstown, New York • Portland, Oregon
- Conditions
- Influenza, Respiratory Viral Infection
- Interventions
- Point-of-care molecular testing and treatment of influenza
- Combination Product
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 3 Months and older
- Enrollment
- 1,618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 9
- States / cities
- Burien, Washington • Seattle, Washington
- Conditions
- Virus Diseases
- Interventions
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more